Program in Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Medical Genetics Center, Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.
Mod Pathol. 2019 Jul;32(7):943-956. doi: 10.1038/s41379-019-0211-2. Epub 2019 Feb 8.
Patients with head and neck squamous cell carcinoma are at increased risk of developing a second primary malignancy, which is associated with poor prognosis and early death. To help improve clinical outcome, we aimed to identify biomarkers for second primary malignancy risk prediction using the routinely obtained formalin-fixed paraffin-embedded tissues of the index head and neck cancer. Liquid chromatography-tandem mass spectrometry was initially performed for candidate biomarker discovery in 16 pairs of primary cancer tissues and their matched normal mucosal epithelia from head and neck squamous cell carcinoma patients with or without second primary malignancy. The 32 candidate proteins differentially expressed between head and neck cancers with and without second primary malignancy were identified. Among these, 30 selected candidates and seven more from literature review were further studied using NanoString nCounter gene expression assay in an independent cohort of 49 head and neck cancer patients. Focusing on the p16-negative cases, we showed that a multivariate logistic regression model comprising the expression levels of ITPR3, KMT2D, EMILIN1, and the patient's age can accurately predict second primary malignancy occurrence with 88% sensitivity and 75% specificity. Furthermore, using Cox proportional hazards regression analysis and survival analysis, high expression levels of ITPR3 and DSG3 were found to be significantly associated with shorter time to second primary malignancy development (log-rank test P = 0.017). In summary, we identified a set of genes whose expressions may serve as the prognostic biomarkers for second primary malignancy occurrence in head and neck squamous cell carcinomas. In combination with the histopathologic examination of index tumor, these biomarkers can be used to guide the optimum frequency of second primary malignancy surveillance, which may lead to early diagnosis and better survival outcome.
头颈部鳞状细胞癌患者发生第二原发恶性肿瘤的风险增加,这与预后不良和早期死亡有关。为了帮助改善临床结果,我们旨在使用常规获得的头颈部癌症索引福尔马林固定石蜡包埋组织来识别第二原发恶性肿瘤风险预测的生物标志物。最初对头颈鳞状细胞癌患者的 16 对原发性癌症组织及其匹配的正常黏膜上皮进行了候选生物标志物的发现,采用液相色谱-串联质谱法。在一个独立的 49 例头颈部癌症患者队列中,使用 NanoString nCounter 基因表达测定法进一步研究了 32 种差异表达的候选蛋白和文献综述中另外 7 种候选蛋白。在这些蛋白中,选择了 30 种候选蛋白和另外 7 种蛋白进行研究,研究重点放在 p16 阴性病例上,我们发现包含 ITPR3、KMT2D、EMILIN1 表达水平和患者年龄的多变量逻辑回归模型可以准确预测第二原发恶性肿瘤的发生,敏感性为 88%,特异性为 75%。此外,通过 Cox 比例风险回归分析和生存分析,发现 ITPR3 和 DSG3 的高表达水平与第二原发恶性肿瘤发展的时间较短显著相关(对数秩检验 P=0.017)。总之,我们鉴定了一组基因,其表达可能作为头颈部鳞状细胞癌中第二原发恶性肿瘤发生的预后生物标志物。与指数肿瘤的组织病理学检查相结合,这些生物标志物可用于指导第二原发恶性肿瘤监测的最佳频率,这可能导致早期诊断和更好的生存结果。